Table 1 Baseline description of patients with RA who were positive and negative for serum anti-hPAD4 IgG
Anti-hPAD4 positive (17 of 40 patients)Anti-hPAD4 negative (23 of 40 patients)p Value
Age (years), n = 4052.1 (13.7)56.0 (11.7)NS
RA duration (years), n = 4014.0 (8.9)9.7 (6.3)NS
Female sex (%), n = 409470NS
ESR (mm/h), n = 3236 (15–54)29 (8–55)NS
CRP (mg/l), n = 318 (2–26)10 (4–24)NS
28-SJC, n = 3610 (9–18)8 (5–12)0.028
28-TJC, n = 3612 (5–19)6 (3–14)NS
DAS28 (1–10), n = 306.1 (4.8–7.1)5.2 (4.3–5.8)0.049
MHAQ (1–4), n = 341.8 (1.4–2.3)1.9 (1.4–2.0)NS
RF IgA+ (%), n = 4052.943.5NS
RF IgM+ (%), n = 4088.278.3NS
Anti-CCP+ (%), n = 4076.591.3NS
vdHSharp erosions (range 0–160), n = 398.5 (5.3–30.0)8.0 (2.0–19.0)NS
vdHSharp JSN (range 0–120), n = 3930.5 (14.0–66.8)16.0 (3.0–42.0)0.047
vdHSharp total (range 0–280), n = 3941.0 (20.4–84.3)25.0 (8.0–61.0)NS
  • Anti-CCP, anticyclic citrullinated peptide CRP; C-reactive protein; ESR, erythrocyte sedimentation rate; JSN, joint space narrowing; MHAQ, Modified Health Assessment Questionnaire; NS, not significant; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; vdHSharp, van der Heijde–modified Sharp.

  • Categorical variables are given as %; age and disease duration are given in mean (SD); and other continuous variables are given in median (IQR).